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Abstract  
Background: Hippocampal enlargements are commonly reported following 
electroconvulsive therapy (ECT). To clarify mechanisms, we examined if ECT-
induced hippocampal volume change relates to dose (number of ECT sessions and 
electrode placement) and acts as a biomarker of clinical outcome.  
Methods: Longitudinal neuroimaging and clinical data from ten independent sites 
participating in the Global ECT-MRI Research Collaboration were obtained for mega-
analysis. Hippocampal volumes were extracted from structural MR images, acquired 
before and after patients (n=281) experiencing a major depressive episode 
completed an ECT treatment series using right unilateral (RUL) and bilateral (BL) 
stimulation.  Untreated non-depressed controls (n=95) were scanned twice. 
Results: The linear component of hippocampal volume change was 0.28%, 0.08 SE, 
per ECT session, p<0.001. Volume change varied by electrode placement in the left 
(BL: 3.3 ± 2.2%, d=1.5; RUL: 1.6 ± 2.1%, d=0.8; p<0.0001), but not the right 
hippocampus (BL: 3.0 ± 1.7%, d=1.8; RUL: 2.7 ± 2.0%, d=1.4; p=0.36,). Volume 
change for electrode placement per CT session varied similarly by hemisphere. 
Individuals with greater treatment-related volume increases had poorer outcomes 
(MADRS change -1.0, 0.35 SE, per 1% volume increase, p=0.005), although effects 
were not significant after controlling for ECT number (slope: -0.69, 0.38 SE, 
p=0.069).  
Conclusions: The number of ECT sessions and electrode placement impacts the 
extent and laterality of hippocampal enlargement, but volume change is not 
positively associated with clinical outcome. Results suggest the high efficacy of ECT 
is not explained by hippocampal enlargement, which alone, might not serve as a 
viable biomarker for treatment outcome.  
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Introduction 
Major depression is the leading cause of disability worldwide (1), yet standard 
treatments for depression are only moderately successful (2). There is thus a need 
to better understand the mechanisms of successful response to antidepressant 
therapies, which may then inform more effective treatment interventions for patients 
with major depression. Though depression is typically treated with different forms of 
psycho- or pharmacotherapies, electroconvulsive therapy (ECT) is still regarded as 
the most effective acute treatment for severe and treatment resistant major 
depressive episodes (3). With ECT, electrical current is applied through scalp 
electrodes, intentionally inducing a seizure, typically 2-3 times per week. When 
administered with modern techniques under anesthesia, ECT is well tolerated and 
has a good safety record. Yet, despite its safety and efficacy (3), the neurobiological 
underpinnings of ECT response, as with other forms of antidepressant treatment, 
remain unclear. Establishing objective biomarkers of clinical response could allow for 
the timely implementation of alternative treatment strategies in unresponsive 
patients. 
  
Most neuroimaging studies of ECT demonstrate treatment-related volume increase 
of the hippocampus (4-9), which suggests that hippocampal volume may serve as a 
biomarker of clinical response. These observations together with data from 
preclinical studies are taken as evidence to support the neurogenic theory of 
depression (10). In particular, translational models provide evidence to suggest that 
a decrease of adult neurogenesis in the hippocampus is associated with depression 
and can potentially be reversed with ECT (10-12). This hypothesis is supported by 
observations that the human hippocampus harbors neuronal stem cells that 
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proliferate throughout life (13), that the volume of the hippocampus is frequently 
reported as reduced in depression (14), and that in an animal model of ECT, a dose-
dependent increase in neurogenesis is seen (15). However, the mechanisms 
underlying ECT-related volume enlargement of the human hippocampus remain 
unclear, and associations with clinical outcome have not been demonstrated 
conclusively (9).  
 
In ECT practice, the number of treatments in an ECT index series typically depends 
on severity of depression and the speed of recovery, such that unresponsive patients 
tend to receive more ECT sessions on average (16). Bilateral (BL) electrode 
placement is widely used for stimulation. However, to mitigate risk for cognitive side 
effects, particularly for verbal and retrograde autobiographical memory, the use of 
other electrode montages are also standard practice (17-19). In particular, right 
unilateral (RUL) ECT, which was developed in an effort to reduce the spread of 
seizure activity to brain areas such as left temporal cortex important for verbal 
memory, is often used as a first line form of ECT (17, 18). Computational modelling 
of electric fields supports that bilateral ECT leads to more diffuse brain stimulation 
than more focal RUL ECT (20, 21). Both the number of ECT sessions received and 
electrode placement may thus impact the extent and laterality of hippocampal 
neuroplasticity and in turn the mechanisms of treatment response. However, prior 
studies have lacked the sample sizes and statistical power needed to investigate the 
moderating effects of these parameters, or have simply controlled for these factors 
as nuisance variables. Consequently, no clear associations between dose or mode 
of electrode placement and measured hippocampal structural changes have 
emerged (12, 22, 23).  
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To address the clinical relevance of ECT-related hippocampal volume change, we 
included 281 patients from the Global ECT-MRI Research Collaboration (GEMRIC) 
(24), and analyzed volume changes of the hippocampus after serial ECT treatment. 
With the largest and most geographically diverse sample to date, and by using an 
optimized image processing pipeline, we obtained sufficient statistical power to 
probe for relationships between hippocampal volume, dose response (number of 
sessions as well as electrode placement) and symptom improvement of relatively 
small effects (24) (f2 = 0.03, α=.05, Power=.80, as estimated for a linear model with 
1,280 degrees of freedom). Changes in hippocampal volume in untreated non-
depressed controls scanned at two different time points were also assessed to 
estimate the variance associated with repeated measures over time. 
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Methods and Materials 
Participants. The clinical and demographic characteristics of the GEMRIC sample 
are summarized in Table 1, as also detailed in (24). Data from 10 sites were 
available, including n=281 patients (59.8% female, age 54.8 ± 16.4) and n=95 
healthy controls (60% female, age 46.9 ± 14.6). Patients were scanned before and 
after ECT, and controls were scanned at two time points without receiving ECT. Due 
to some missing data points (e.g. follow up scan, number of ECTs, or depression 
score), the sample sizes for the statistical models used to test for the effects of ECT 
number or relationships with clinical outcome ranged from 250 to 268 patient 
participants. ECT practice varied among contributing sites in terms of electrode 
placement and/or stimulation parameters as detailed previously (24). Concurrent 
psychotropic medications were used at most sites, as describe in Supplemental 
information. To test for the effects of electrode placement, only patients that received 
exclusively RUL (n=149) or BL (n=50; 10 bifrontal (BF), 40 bitemporal (BT)) 
treatment throughout all sessions of the ECT index series were included for analysis. 
All sites contributing data received approval by their local ethical committees or 
Institutional Review Board, and the centralized mega-analysis was approved by the 
Regional Ethic Committee South-East in Norway (2013/1032 ECT and 
Neuroradiology, June 1st 2015). 
 
Image acquisition and post processing. The image processing methods have 
been detailed previously (24). Briefly, T1-weighted MRI volumes with a minimal 
resolution of 1.3 mm in any direction were acquired before and after (typically within 
1-2 weeks) an ECT treatment series using 1.5T (1 site) or 3T (9 sites) scanners. 
Raw structural MRI data from each site were uploaded to a common server and 
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were analyzed together using the same preprocessing steps. During preprocessing, 
images were corrected for scanner specific gradient non-linearity (25), registered to 
a common atlas space and resampled to an isotropic 1 mm3 spatial resolution. 
Further processing was performed by FreeSurfer version 5.3, and Quarc (26) was 
used for unbiased estimation of hippocampal volume change. The automated 
segmentation of FreeSurfer for hippocampal volume measurement has been shown 
to be comparable to results from manual tracings (27-29). Depressive symptoms 
were rated by the Montgomery-Åsberg Depression Rating Scale (MADRS). For sites 
collecting only the 17- or 24-item Hamilton Depression Rating Scale (HAM-D), a 
validated equation was used to convert HAM-D-17 to MADRS scores (30).  
 
For all modes of electrode placement employed across sites, one of the electrodes 
was placed over the right (non-dominant) hemisphere, hence the right hippocampus 
was chosen for primary analysis to determine dose effects of repeated ECT 
treatments and relationships with clinical response, weighting ECT session similarly 
regardless of participant variations for electrode placement within or across sites. 
The same effects were examined for the left hippocampus and results from these 
analyses are provided in the Supplement. Follow-up analyses were performed to 
examine the effects of BL and RUL electrode placement on both the right and left 
hippocampus, excluding one patient that received left anterior right temporal (LART) 
and patients who received a combination of RUL and BL during the index series. 
Quality control of hippocampal segmentation was performed by procedures adapted 
from the ENIGMA consortium (http://enigma.usc.edu/) (31).  
 
Statistical analysis. Statistical analysis was performed with the R software 
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package, version 3.3.1 (32). Slopes from linear models are reported with ± Standard 
Error (SE) and all other results are reported as Mean ± Standard Deviation (SD). 
Primary analyses addressed relationships between 1) the number of ECT sessions 
and hippocampal volume change, and 2) hippocampal volume change and change 
in MADRS score pre to post ECT using the General Linear Model (GLM). In a 
subsample of patients receiving only BL or RUL ECT, effects of electrode placement 
were additionally examined, and differences in slopes were tested using the function 
linearHypothesis in R (car-package, version 2.1-6). To control for and evaluate non-
linear effects, the number of ECT sessions squared was included as a covariate. To 
control for Age, Sex, Site, baseline hippocampal volume and baseline depression 
score, these variables were included as covariates in the models as specified in the 
Results. Considering our a priori hypotheses and the large amount of literature 
showing changes in hippocampal volume with ECT (9), individual tests were 
considered significant at a level of p < 0.01, corresponding to a Bonferroni correction 
for 5 independent hypotheses. In the results figures, the regression lines (with 95% 
confidence intervals shown as shaded areas) represent the relationships between 
dependent and independent variables calculated without covariates. Cohen´s d for 
volume change was calculated as mean change/SD. Finally, relationships between 
volume change and number of ECT sessions were additionally examined in 
responders (patients who showed >50% change in MADRS score over the course of 
ECT, n = 150) versus non-responders (n = 98) using Welch Two Sample t-tests (two-
sided).  
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Results 
First, we tested whether volume change of the hippocampus is positively associated 
with number of ECT sessions over time, including number of ECTs squared (to 
estimate non-linear effects), Age, Sex, Site, baseline depression score, and baseline 
hippocampal volume as covariates. For the right hippocampus, we found that the 
linear component (slope) of volume change (%) versus number of ECTs was 0.28 ± 
0.083, (t(225) = 3.35, p < 0.001). The square term was near significant -0.0048 ± 
0.002, (t(225) = -1.94, p = 0.053), suggesting a sub-linear relationship (Figure 1A) 
that reflects larger volume changes occur early in the ECT treatment series. When 
comparing control subjects scanned at two distinct time points, no significant 
changes in hippocampal volume were observed; mean 0.05 % ± 0.08, d = 0.06, n = 
95; p = 0.54 (One Sample t-test). Results for the left hippocampus, which are 
presented in the Supplement, showed similarly significant volume enlargement with 
increasing number of ECT sessions. Mean volumes are provided in Table 1. 
 
Next, we tested whether clinical outcome following ECT, measured using the 
MADRS, is positively associated with change in right hippocampal volume, when 
controlling for effects of Age, Sex, Site, baseline depression score and baseline 
hippocampal volume. Contrary to our hypothesis that patients with greater clinical 
response would exhibit larger volume increases, we found a negative relationship 
(slope -1.0 ± 0.35, t(233) = -2.84, p < 0.005) (Figure 1B) indicating less change in 
those with the greatest improvement. Separating patients based on the extent of 
clinical response over the course of ECT, volume change (%) was 2.6 ± 2.0, d = 1.3 
and 3.3 ± 1.7, d = 1.9 for responders (those with > 50% improvement in mood 
scores) and non-responders, respectively (p = 0.009, Figure 1C).  However, we also 
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observed that the number of ECT sessions was associated with worse outcome 
(Figure 1D and see Supplemental information) such that non-responders were 
prescribed and received more sessions than responders (13.2 ± 4.7 versus 11.5 ± 
5.3, t(232.11) = 2.74, p = 0.007). Thus, to control for differences in the length of 
treatment for responsive versus non-responsive patients, the number of ECT 
sessions was additionally included as covariate to the model addressing the 
relationship between change in hippocampal volume and change in mood rating. 
When additionally controlling for the number of ECT sessions, the slope of change in 
MADRS score versus volume change remained negative, but was no longer 
significant (-0.69 ± 0.38, t(225) = -1.83, p = 0.069). The effect size of hippocampal 
volume change (partial eta squared) was 0.03 and 0.01 before and after adding 
number of ECT sessions as a covariate. As shown in the Supplement, positive 
relationships between left hippocampal volume enlargement and clinical change 
were also absent. Follow-up analyses examining effects of ECT number and 
relationships with clinical outcome in ECT responders and non-responders for both 
the left and right hippocampus are also presented in the Supplemental information 
(see Figure S1). 
 
Finally, to investigate the effects electrode placement, we constructed separate 
linear models for change in volume for the right and left hippocampus with separate 
slopes for the number of RUL or BL ECT sessions, controlling for Age, Sex, Site, 
baseline depression score and baseline hippocampal volume. For the right 
hippocampus (Figure 2A), the slopes of volume change per ECT session for RUL 
and BL electrode placement were both ~0.13, suggesting similar effects for number 
of BL and RUL treatments. Change in volume (mean ± SD) was also similar for BL 
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and RUL electrode placement, 3.0 ± 1.7%, d = 1.8 and 2.7 ± 2.0%, d = 1.4, p = 0.36, 
t-test, respectively. For the left hippocampus (Figure 2B), the slope of volume 
change (slope ± SE) versus number of treatments was steeper for BL (0.18 ± 0.03, p 
= 1.9 x 10-7) than RUL (0.06 ± 0.04, p = 0.15) electrode placements (p = 0.007, 
Linear hypothesis test). Change in left hippocampal volume was also greater for BL 
with respect to RUL stimulation (BL: 3.3 ± 2.2%, d = 1.5; RUL: 1.6 ± 2.1%, d = 0.8, p 
= 1.5 x 10-5, t-test). The effect of electrode placement on the left hippocampal 
volume change was further confirmed by a number of ECTs-by-electrode placement 
interaction (p = 0.007) in a model of left hippocampal volume change versus number 
of ECTs where electrode placement was included as a separate covariate (see 
Supplemental Information, Model 2c).  
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Discussion 
Including the largest sample of patients with ECT studied with neuroimaging 
methods to date, our findings showed a highly significant number of ECT session 
dose-dependent biological effect of ECT on hippocampal volume. We also showed 
that electrode placement differentially affects the extent of volume change in the right 
and left hippocampus. Specifically, BL stimulation accounts for similar changes in 
volume for both the right and left hippocampus, but RUL stimulation lead to more 
focal effects in the right hippocampus. However, contrary to our expectations, we 
also found that volume enlargement of the hippocampus is not significantly related to 
treatment outcome. Instead, results showed a negative relationship between 
hippocampal volume and symptom improvement such that individuals with greater 
hippocampal enlargement tend to have less response. However, patients with poor 
response received more treatments, and this negative relationship was not 
significant when the number of ECT sessions were taken into account. This finding 
represents a major deviation from the common assumption in the field of a positive 
association between ECT-induced volume enlargement and clinical improvement. 
Rather, results indicate that gross volume increase of the hippocampus by itself is 
not a meaningful biomarker for positive therapeutic response. 
 
Findings from this study showed that ECT dose parameters including the number of 
ECT sessions received and the location of electrode placement modulated the 
magnitude and hemispheric specificity of hippocampal volume change. Here, results 
demonstrated a clear and dose-dependent effect of number of ECT sessions on 
hippocampal volume in both the right and left hemispheres.  Further, RUL and BL 
ECT showed differential effects on volume change in the left and right hippocampus. 
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Existing data supports that the antidepressant efficacy and cognitive side effects of 
ECT are influenced by electrode position as well as other stimulus parameters (17, 
33, 34). Designed to reduce cognitive side effects, with RUL electrode placement, 
electrical stimulation is focused away from the dominant (left) hemisphere (35). In 
contrast, the right side of the brain is targeted by both RUL and BL electrode 
placements. Hence, if the electrical stimulus is modulating the volume change, a 
clear difference in volumetric effect of RUL versus BL stimulation for the left 
hippocampus is expected. In line with this hypothesis, and computational modelling 
results showing more prominent electric field increases in the right hemisphere for 
RUL ECT and in both hemispheres for BL ECT (20, 21), our results show volume 
increases are greater in the right hippocampus for RUL, while BL ECT leads to 
similar volume increases in both hemispheres (Figure 2).  
 
Though we have shown that hippocampal volume enlargement is influenced by ECT 
dose parameters, the clinical relevance of these changes remains unclear.  ECT-
induced volume enlargement of the hippocampus (4-8) has led to the suggestion that 
treatment-related neuroplasticity may underlie symptom improvement (12). From a 
mechanistic perspective, stress in combination with genetic or epigenetic factors 
may reduce neurogenesis and precipitate a depressive episode, and antidepressant 
therapies (such as ECT) might work through restoration of the basal rate of 
neurogenesis in the hippocampal dentate gyrus (11). Since both left (Figure S1B and 
D) and right (Figure 1) hippocampal volume change relates to the number of ECT 
treatments received, but does not positively associate with clinical outcome, 
enlargement of the hippocampus may be an epiphenomenon of ECT. Overall 
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enlargement of hippocampal volume observed with ECT may thus relate to seizure 
therapy itself rather than to the therapeutic effects of treatment. 
 
Our results have important implications for treatment management and raise several 
questions and challenges relevant to understanding the neurobiological 
underpinnings of ECT. It is a common experience among ECT-practitioners that the 
patients with the highest depression scores tend to be the ones with the higher 
response rates (36), and often these patients respond quickly. At the same time, 
longer depressive episodes and medication failure at baseline are indicators of poor 
response to ECT (37). The number of treatments prescribed is typically based on 
clinically determined response, and patients with modest response are thus more 
likely to receive a larger number of ECT sessions in the index series (16). However, 
while the biological effects of ECT may be expected to relate to the number of 
treatments received, as shown for growth of the hippocampus, there is not an 
apparent parallel regarding improvement in depression score (Figure 1D).  
 
It is conceivable that several different biological processes impact ECT clinical 
response and these might or might not overlap with the biological manifestations of 
seizure therapy itself. Animal studies support that in addition to neurogenesis, 
multiple other neurophysiological and neuroplastic changes occur following 
electroconvulsive shock (ECS). Thus, it is possible that particular micro-
environmental events may influence the overall macroscopic structure of the 
hippocampus, while separate or concurrent processes constitute the mechanisms 
underlying antidepressant response. For example, changes in cellular or synaptic 
density and intra/extracellular fluid might impact gross changes in hippocampal 
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volume. Animal models have shown dose-dependent increase in markers of 
hippocampal neural, glial and endothelial cell proliferation and density following ECS 
(15, 38-40) that may result in an absolute increase in the number of synapses or 
specific cell types (41). Notably, a dissociation between neural changes and 
behavior was reported in a recent animal model study, where ECT was shown to 
stimulate neurogenesis, but the number of new neurons did not predict the extent of 
behavioral outcome (42). These results are compatible with our findings with respect 
to the absence of clinical response relationships. At the same time, hippocampal 
volume may be influenced by fluid content, which may vary as a consequence of 
increased vascularization (43) and blood flow (44, 45), or inflammation (46-48) as 
supported by an observed ECS upregulation of markers for microglia (49, 50).  
 
Other molecular effects, not necessarily independent, may relate more directly to 
antidepressant response. For example, ECS is also shown to modulate 
monoaminergic neurotransmission (51), as similar to standard antidepressant 
treatment. Increased expression of brain-derived neurotrophic factor (BDNF) (52, 53) 
and vascular endothelial growth factor (VEGF) (54) are also reported with ECS or 
ECT in humans, and have been linked to changes in behavior (52, 55). Further, ECS 
elicits a number of hippocampal epigenetic modifications, including GADD45B-
dependent DNA demethylation (56), and the alteration of histone and DNA modifying 
enzymes (57), which may influence structural neuroplasticity at both the macro and 
micro-scale.  
 
It is also possible that neurogenesis or other neurotrophic or neurophysiological 
events induced by ECT may precede or lag behind clinical response. Further, 
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variations in the morphology of different regions of the hippocampus (for example, 
the dentate gyrus or the anterior hippocampus with more connections to neural 
circuits associated with mood regulation and emotional behavior) may be more 
sensitive to ECT outcome. For example, analyses of change in hippocampal shape 
with ECT have indicated greater regional changes in the right anterior hippocampus 
(12), as well as changes specific to particular hippocampal subfields (7). A recent 
study in 24 subjects also suggested that volumes of hippocampal subfields at 
baseline could predict response to ECT treatment (58), however this finding needs 
replication in larger samples. 
 
Our study has some limitations, most notably the design is retrospective (e.g. no a 
priori standardization of MR protocols or depression scoring) and assessments were 
limited to before- and after treatment. Further, the design was naturalistic, so 
patients who remained unresponsive were prescribed a greater number of ECT 
sessions on average. Other unknown moderators or speed of response, which can 
impact clinical decisions regarding the number of treatments prescribed (59), remain 
similarly unaccounted for. For example, other stimulation parameters such as pulse 
width and frequency and seizure threshold may also impact neural changes. 
However, since these parameters varied across sites, including during the ECT 
treatment series for individual patients, they were not investigated. Animal studies 
have also shown that both ECS, and to a lesser extent, chronic antidepressant 
treatment impact neurogenesis in the rat hippocampus (38). It is thus possible that 
the continuation of psychotropic medication during ECT might impact hippocampal 
structure. However, follow-up analysis revealed the extent of volume change was 
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similar for participants tapered off all antidepressants, benzodiazepines and 
anticonvulsants during ECT (Figure S2). 
 
Cognitive side effects remain a fundamental concern in ECT practice, and were not 
examined in this study and thus warrant future research. Future studies would also 
benefit from including repeated assessments at multiple time points throughout 
treatment to allow examination of the trajectories and speed of change, and explore 
ways of subgrouping depressed individuals, possibly by identifying biological 
subtypes (60).  Implementing machine-learning approaches, with a goal of identifying 
individuals that are likely to respond to ECT (61), and investigations using higher 
resolution imaging approaches to investigate sub-regions of the hippocampus (58) 
may also advance the field. Another avenue of future research would be studies with 
standardized ECT protocols across all participants to reduce confounds and increase 
the power of the designs to identify moderators conclusively. New approaches are 
needed to identify biomarkers that can explain and predict the clinical effect of ECT, 
separate from seizure or other procedural effects, which also may inform other 
antidepressant treatments. 
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Figure Legends 
 
Figure 1 | Differential effect of ECT on hippocampal volume and clinical 
outcome. A, Scatter plot of volume change of the right hippocampus, computed as 
(posttreatment – pretreatment score)/pretreatment score x 100, versus number of 
ECTs; n = 241. Slope (controlling for number of ECTs squared, Age, Sex, Site, 
baseline depression score, and baseline hippocampal volume), 0.28 ± 0.08, (t(225) = 
3.35, p < 0.001. B, Scatter plot of change in MADRS score, computed as 
pretreatment – posttreatment score, versus volume change of the right 
hippocampus; n = 248. Slope (controlling for Age, Sex, Site, baseline depression 
score and baseline hippocampal volume), -1.0 ± 0.35, t(233) = -2.84, p < 0.005.  C, 
Boxplot comparing volume change of the right hippocampus in non-responders 
(MADRS reduction < 50%) versus responders (MADRS reduction > 50%), n = 248, 
t(234.13) = 2.62, p = 0.009. D, Scatter plot of change in MADRS score versus 
number of ECTs; n = 268. Slope (controlling for age, Sex and Site), - 0.28 ± 0.16, 
t(256) = -1.80, p = 0.074). Non-responders received more ECT sessions (13.2 ± 4.7 
versus 11.5 ± 5.3, t(232.11) = 2.74, p = 0.007) than responders.  
 
Figure 2 | Effect of electrode placement on change in left and right 
hippocampal volume. A. Changes in right hippocampal volume per number of ECT 
sessions for bilateral (BL, dashed line) and right unilateral (RUL, solid line) electrode 
placement. Both slope and change in volume was similar for BL and RUL ECT 
(slope: both ~.13; BL volume increase: 3.0 ± 1.7%, RUL volume increase: 2.7 ± 
2.0%). B. Changes in left hippocampal volume per number of ECT sessions for BL 
(dashed line) and RUL (solid line) electrode placement. Slope was steeper and 
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volume change was greater for BL (slope: 0.18 ± 0.03; volume increase: 3.3 ± 2.2%) 
than RUL (slope: 0.06 ± 0.04; volume increase: 1.6 ± 2.1%) stimulation. 
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Characteristics of subjects  
 Mean SD n# 
Controls       
Age 46.9 14.6 95 
Baseline right hippocampal volume (mm3) 4052.5 446.2 95 
Change in right hippocampal volume (%) 0.05 0.8 95 
Baseline left hippocampal volume (mm3) 3948.0 444.3 95 
Change in left hippocampal volume (%) 0.01 0.7 95 
Baseline intracranial volume (cm3) 1520.2 179.2 95 
Patients    
Age 54.9 16.4 281 
Baseline right hippocampal volume (mm3) 3774.1  588.3 254$ 
Change in right hippocampal volume (%) 2.9 1.9 250^ 
Baseline left hippocampal volume (mm3) 3657.9 561.0 254$ 
Change in left hippocampal volume (%) 2.2 2.3 250^ 
Baseline intracranial volume (cm3) 1505.9 175.6 254$ 
Baseline depression score 33.3 8.2 279 
Post treatment depression score 15.0 11.0 277 
Duration of episode (months) 20.1 31.6 158 
Number of ECTs, total 12.0 5.2 273* 
   Number of ECTs, BL only  14.6 7.5 50 
   Number of ECTs, RUL only 10.9 3.6 149 
Number of ECTs, responders 11.5 5.3 166 
Number of ECTs, non-responders 13.2 4.7 102 
 
Table 1 The number of subjects (#) vary because of missing data for some variables. 
Information about number of ECTs (*) was missing for 8 subjects; some subjects received 
more than one form of lead placement and one subject also received LART stimulation. A 
total of 27 subjects ($) were missing MRI at either before or after treatment (baseline volume 
is not reported for these) and 4 subjects failed automated processing of volume change (^). 
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Volume of the Human Hippocampus and Clinical Response  
Following Electroconvulsive Therapy 
 
Supplemental Information 
 
 
Volume change and clinical outcome for the left hippocampus 
 
Volume growth was associated with the number of ECT sessions for both the right (see main 
text) and the left hippocampus (t(225) = 3.93, p < 0.001). Controlling for the number of ECT 
sessions, relationships between change in clinical response and change in hippocampal 
volume were not significant for the right (see main text) or left hippocampus (t(225) = -1.50, 
p = 0.14). 
 
Volume change for ECT responders and non-responders 
 
Although the number of ECT sessions received for individual patients was confounded by 
the extent of their clinical response, understanding how clinical response relates to length of 
treatment provides further insight. Specifically, a model of change in MADRS score as a 
function of number of treatments showed a negative association F(1,266) = 7.96, slope =                  
-0.41, p = 0.005, R2 = 0.03 (Figure S1D), although after correcting for Age, Sex and Site this 
was not significant (slope = -0.28, t(256) = -1.80, p = 0.074). Hence, follow up analyses were 
performed to further clarify the effects of volume change and ECT session number in ECT 
responders and non-responders. First, we tested for the effect of response group 
(responder, non-responder) on hippocampal volume change, correcting for number of ECTs 
and number of ECTs squared, and found that the effect of group was not significant for the 
right (-0.35, t(236) = -1.41, p = 0.16), or the left (-0.50, t(236) = -1.78, p = 0.08) hippocampus 
(Figure S1A and B, respectively). Also, looking at responders separately from non-
responders (Figure S1C and D) did not reveal positive relationships between volume change 
and clinical outcome (change in MADRS score) for the right or left hippocampus. Similarly, 
there was no positive association between number of ECTs and outcome for responders 
separated from non-responders (Figure S1E). Finally, to completely exclude variance 
associated with number of treatments, we used data from a subset of patients that received 
exactly 12 ECT sessions (the mode number of treatments). Again, a model of change in 
MADRS score as a function of volume change did not yield a significant relationship (F(1,45) 
= 0.006, p = 0.94, R2 = 0.0001) (Figure S1F).  
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Figure S1. Effect of ECT on hippocampal volume and clinical outcome for responders and non-
responders. A, Scatter plot of volume change for the right hippocampus versus number of ECTs in responders 
(blue) and non-responders (red); n = 241. B, Scatter plot of volume change for the left hippocampus versus 
number of ECTs in responders (blue) and non-responders (red); n = 241. C, Scatter plot of change in MADRS 
score versus volume change for the right hippocampus in responders (blue) and non-responders (red); n = 247. 
D, Scatter plot of change in MADRS score versus volume change for the left hippocampus in responders (blue) 
and non-responders (red); n = 247. E, Scatter plot of change in MADRS score versus number of ECTs in 
responders (blue) and non-responders (red); n = 267. F, Scatter plot of change in MADRS versus number of 
ECTs including patients only receiving ≤ 12 sessions classified as responders (blue) and non-responders (red); n 
= 171. 
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Supplementary Methods 
 
Medications: Concurrent psychotropic medications were used at most sites, but there was 
virtually no change in medication during treatment (number of patients receiving each 
medication at baseline: antidepressants (n = 115), antipsychotics (n = 93), lithium (n = 0), 
other mood stabilizer (n = 35) or benzodiazepines (n = 56)). Information about dose was not 
available. Volume change of the right hippocampus did not differ between one site that 
tapered patients off all antidepressants, benzodiazepines and anticonvulsants (Figure S2) 
compared to all other sites (p = 0.27). 
 
 
 
Electrode placement and clinical outcome: No significant difference for electrode 
placement was found when modelling separate slopes for RUL and BL stimulation (Figure 
S3). 
 
 
0
20
40
0 10 20 30 40
Number of ECTs
MA
DR
S c
ha
ng
e (
pre
−p
os
t)
Stimulation type
BL
RUL
Lead placement and outcome
−5
0
5
10
0 10 20 30 40
Number of ECTs
Vo
lum
e c
ha
ng
e, 
rig
ht 
hip
po
ca
mp
us
 (%
)
Treatment & volume change
Figure S2. Scatter plot of volume change of the 
right hippocampus versus number of ECTs for 
the site that tapered patients off all medications 
before treatment. The mean volume change at this 
site was 2.6%, which did not differ from all other sites 
(2.9%), p = 0.27 t-test.  
 
Figure S3. Treatment and clinical outcome for RUL 
and BL. Scatter plot of change in MADRS score 
versus number of ECTs for BL and RUL electrode 
placements. In a model with BL and RUL as separate 
predictors (controlling for age, sex, site, and baseline 
depression score), the slopes were -0.27 and -0.53 for 
BL and RUL stimulation, respectively. These slopes 
were not significantly different (p = 0.25, Linear 
Hypothesis test).  
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Supplementary results, complete statistical models 
 
The full linear models for our main analysis are provided below. The model name 
corresponds to results presented in the Figures and in the main text.  
  
Model 1a 
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Model 1b 
 
 
Model 1b including the number of ECT sessions 
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Model 1d 
 
 
Model 2a 
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Model 2b 
  
 
Model 2c 
 
